Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

929 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.
Nakayama Y, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Yamamoto W, Ebina K, Hata K, Hiramatsu Y, Katayama M, Son Y, Amuro H, Akashi K, Onishi A, Hara R, Yamamoto K, Ohmura K, Matsuda S, Morinobu A, Hashimoto M. Nakayama Y, et al. Among authors: hiramatsu y. Rheumatol Int. 2022 Jul;42(7):1227-1234. doi: 10.1007/s00296-021-05086-w. Epub 2022 Mar 10. Rheumatol Int. 2022. PMID: 35266034
Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.
Nakayama Y, Hashimoto M, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Yamamoto W, Ebina K, Hata K, Hiramatsu Y, Katayama M, Son Y, Amuro H, Akashi K, Onishi A, Hara R, Yamamoto K, Ohmura K, Matsuda S, Morinobu A. Nakayama Y, et al. Among authors: hiramatsu y. Scand J Rheumatol. 2022 Nov;51(6):431-440. doi: 10.1080/03009742.2021.1947005. Epub 2021 Sep 13. Scand J Rheumatol. 2022. PMID: 34511031
Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: An ANSWER cohort study.
Makino H, Kotani T, Hata K, Nishioka D, Yamamoto W, Yoshikawa A, Wada Y, Hiramatsu Y, Shiba H, Nagai K, Katayama M, Son Y, Amuro H, Onishi A, Akashi K, Hara R, Hirano T, Hashimoto M, Takeuchi T. Makino H, et al. Among authors: hiramatsu y. Mod Rheumatol. 2023 Aug 25;33(5):928-935. doi: 10.1093/mr/roac115. Mod Rheumatol. 2023. PMID: 36112486
Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study.
Shiba H, Kotani T, Nagai K, Hata K, Yamamoto W, Yoshikawa A, Wada Y, Hiramatsu Y, Makino H, Ueda Y, Onishi A, Murata K, Amuro H, Son Y, Hara R, Hirano T, Ebina K, Katayama M, Hashimoto M, Takeuchi T. Shiba H, et al. Among authors: hiramatsu y. Int J Mol Sci. 2023 Apr 17;24(8):7399. doi: 10.3390/ijms24087399. Int J Mol Sci. 2023. PMID: 37108561 Free PMC article.
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K, Etani Y, Maeda Y, Okita Y, Hirao M, Yamamoto W, Hashimoto M, Murata K, Hara R, Nagai K, Hiramatsu Y, Son Y, Amuro H, Fujii T, Okano T, Ueda Y, Katayama M, Okano T, Tachibana S, Hayashi S, Kumanogoh A, Okada S, Nakata K. Ebina K, et al. Among authors: hiramatsu y. RMD Open. 2023 Aug;9(3):e003160. doi: 10.1136/rmdopen-2023-003160. RMD Open. 2023. PMID: 37597846 Free PMC article.
Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021- the ANSWER cohort study.
Yamada H, Jinno S, Maeda T, Hayashi S, Yamamoto W, Onishi A, Onizawa H, Takeuchi T, Hiramatsu Y, Okita Y, Ebina K, Son Y, Yoshida N, Watanabe R, Hara R, Yamashita M, Nose Y, Yamamoto Y, Okano T, Nishimura K, Ueda Y, Sendo S, Hashimoto M, Kuroda R, Saegusa J. Yamada H, et al. Among authors: hiramatsu y. Rheumatology (Oxford). 2023 Oct 4:kead539. doi: 10.1093/rheumatology/kead539. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37792494
Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.
Shirasugi I, Onishi A, Nishimura K, Yamamoto W, Murakami K, Onizawa H, Maeda Y, Ebina K, Son Y, Amuro H, Katayama M, Hara R, Nagai K, Hiramatsu Y, Hashimoto M, Okano T, Maeda T, Hayashi S, Sendo S, Jinno S, Yamamoto Y, Yamada H, Ueda Y, Saegusa J. Shirasugi I, et al. Among authors: hiramatsu y. Int J Rheum Dis. 2024 Mar;27(3):e15097. doi: 10.1111/1756-185X.15097. Int J Rheum Dis. 2024. PMID: 38439176
929 results